Copper(II) complexes {[Cu(HL)(ClO4)(H2O)](ClO4)⋅3H2O} (1), {[Cu
(HL)(m-phth)]⋅5H2O} (2) and {[Cu(HL)(NCS)]2(ClO4)2⋅2H2O} (3)
(HL=2-{[2-(1-piperazinyl)ethylimino]methyl}phenol; m-phth=
1,3-benzenedicarboxylate] have been synthesized and characterized
by structural determination and spectroscopic studies.
The mononuclear square pyramidal complex 1 resulted from
the reaction of HL with copper perchlorate hexahydrate. Then
mononuclear square planar complex 2 and dinuclear thiocyanato
bridged complex 3 were obtained by reacting 1 with
disodium 1,3-benzenedicarboxylate (Na2(m-phth)) and potassium
thiocyanate, respectively. The interactions of 1–3 with CTDNA
/ serum albumins were investigated by UV-visible
absorption and fluorescence spectroscopy. The intrinsic binding
constants of 1, 2 and 3 with CT-DNA were calculated. Study of the interactions of 1–3 with
human serum albumin (HSA) / bovine serum albumin (BSA)
showed that all the complexes could quench intrinsic
fluorescence of HSA and BSA through a static quenching
process. Molecular docking technique was utilised to confirm
the mode of interaction of complexes with CT-DNA / serum
albumin. Anticancer activities of the complexes have been
tested using human breast cancer cell lines MCF7 and MBAMB-
231. Among the complexes studied 3 shows the higher
cytotoxic activity and growth inhibition of cancer cells via
induction of apoptotic cell death.
